Waldencast plc
Business
Waldencast plc is a multi-brand beauty and wellness platform that develops, acquires, and scales purpose-driven brands. The company operates two reportable segments: Obagi Medical, a professional skincare brand offering prescription, OTC, and cosmetic products plus hyaluronic acid injectable fillers; and Milk Makeup, a clean prestige makeup brand offering primers, tints, mascaras, and skincare products. Products are distributed domestically through physician-dispensed channels, e-commerce, and retail partners; internationally through distributors, subsidiaries, and licensing agreements across over 95 countries.
Summary from 20-F filed 2026-03-13
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2021 2021-12-31 | FY 2020 2020-12-31 |
|---|---|---|---|
| Formation and operating costs | 9 | — | |
| Loss from operations | −9 | — | |
| Interest income on operating account | 1,146 | — | |
| Interest income on marketable securities held in Trust Account | 52,047 | — | |
| Offering expenses related to warrant issuance | −719,201 | — | |
| Change in fair value of forward purchase agreement liabilities | −2 | — | |
| Change in fair value of warrant liabilities | −3 | — | |
| Total other expense | −5 | — | |
| Net loss | −14 | — | |
| Weighted average shares outstanding, Class A ordinary shares subject to possible redemption (in Shares) | 27 | — | |
| Basic and diluted net loss per share, Class A ordinary shares subject to possible redemption (in Dollars per share) | −0.41 | — | |
| Weighted average shares outstanding, Non-redeemable Class B ordinary shares (in Shares) | 8 | — | |
| Basic and diluted net loss per share, Non-redeemable Class B ordinary shares (in Dollars per share) | −0.41 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2021 2021-12-31 | FY 2020 2020-12-31 |
|---|---|---|---|
| Cash | 2 | — | |
| Prepaid expenses current | 204,821 | — | |
| Deferred offering costs associated with initial private offering | — | 166,792 | |
| Total current assets | 2 | 166,792 | |
| Prepaid expenses non-current portion | 33,050 | — | |
| Investment held in Trust Account | 345 | — | |
| Total assets | 347 | 166,792 | |
| Accounts payable and accrued expenses | 272,953 | 177,743 | |
| Due to related party | 95,000 | — | |
| Total current liabilities | 367,953 | 177,743 | |
| Warrant liabilities | 21 | — | |
| Deferred legal fees | 8 | — | |
| Forward purchase agreement liabilities | 13 | — | |
| Working Capital Promissory Note related party | 2 | — | |
| Deferred underwriters discount | 12 | — | |
| Total liabilities | 57 | 177,743 | |
| Commitments & Contingencies (Note 6) | — | — | |
| Class A ordinary shares subject to possible redemption, 34,500,000 and no shares at redemption value of $10.00 at December 31, 2021 and December 31, 2020, respectively | 345 | — | |
| Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding | — | — | |
| Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; no shares issued and outstanding (excluding 34,500,000 and no shares subject to redemption) at December 31, 2021 and December 31, 2020, respectively | — | — | |
| Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 8,625,000 and no shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively | 863 | — | |
| Additional paid-in capital | — | — | |
| Accumulated deficit | −55 | −10,951 | |
| Total shareholders deficit | −55 | −10,951 | |
| Total liabilities, redeemable ordinary shares and shareholders deficit | 347 | 166,792 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2021 2021-12-31 |
|---|---|---|
| Increase in deferred legal costs | 8 | |
| Change in fair value of warrant liabilities | 3 | |
| Change in fair value of forward purchase agreement liabilities | 2 | |
| Offering costs allocated to warrants | 719,201 | |
| Prepaid assets | −237,871 | |
| Accounts payable and accrued expenses | 272,953 | |
| Due to related party | 95,000 | |
| Net cash used in operating activities | −815,682 | |
| Investment of cash into Trust Account | −345 | |
| Net cash used in investing activities | −345 | |
| Proceeds from issuance of Founder Shares | 25,000 | |
| Proceeds from Initial Public Offering, net of underwriters discount | 338 | |
| Proceeds from issuance of Private Placement Warrants | 9 | |
| Proceeds of Working Capital Promissory Note related party | 2 | |
| Payments of offering costs | 1 | |
| Net cash provided by financing activities | 347 | |
| Net Change in Cash | 2 | |
| Initial value of warrant liabilities | 18 | |
| Deferred underwriters discount payable charged to additional paid-in capital | 12 | |
| Initial value of forward purchase agreement liabilities | 12 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Waldencast plc's CIK number?
Waldencast plc's SEC CIK number is 0001840199 (1840199). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Waldencast plc's SEC filings?
All of Waldencast plc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.